Description: Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program focuses on the development of a therapeutic for correcting the impaired muscle regenerative process in genetic pediatric disease, duchenne muscular dystrophy (DMD), a genetic disease that involves the mutation and functional disruption of the DMD gene and loss of Dystrophin. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Home Page: satellos.com
Royal Bank Plaza
Toronto,
ON
M5J 2J1
Canada
Phone:
647-660-1780
Officers
| Name | Title |
|---|---|
| Mr. Francis Gleeson B.B.A. M.B.A | Co-Founder, CEO, President & Director |
| Ms. Elizabeth Williams C.A., CPA | CFO & Corporate Secretary |
| Dr. Philip Lambert M.A., Ph.D. | Chief Scientific Officer |
| Mr. William Wasyl Jarosz | Executive Director |
| Mr. Warren Whitehead C.M.A., CPA | Head of Corporate Strategy |
| Dr. Michael Cross M.B.A., Ph.D. | Chief Business Officer |
| Dr. Michael A. Rudnicki Ph.D. | Co-Founder & Chief Discovery Officer |
| Mr. J. Robert Hall CFA | Senior Vice President of Finance & Administration |
| Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | Strategic Advisor |
| Ms. Desiree Chan | Chief of Staff |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.5697 |
| Price-to-Sales TTM: | 295.3351 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |